Ospemifene

CAT:
804-HY-B0723-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Ospemifene - image 1

Ospemifene

  • Description :

    Ospemifene (FC-1271a) is an orally active and non-estrogenic selective estrogen receptor modulator (SERM) with Ki values of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene inhibits caspase-3 activity. Ospemifene inhibits neuronal degeneration, prevents bone loss, and increases vaginal weight and vaginal epithelial height. Ospemifene has anticancer activity against breast cancer[1][2][3][4][5][6].
  • Product Name Alternative :

    FC-1271a
  • UNSPSC :

    12352005
  • Hazard Statement :

    H410
  • Target :

    Caspase; Estrogen Receptor/ERR
  • Type :

    Reference compound
  • Related Pathways :

    Apoptosis; Vitamin D Related/Nuclear Receptor
  • Applications :

    Cancer-programmed cell death
  • Field of Research :

    Cancer; Endocrinology; Neurological Disease
  • Assay Protocol :

    https://www.medchemexpress.com/Ospemifene.html
  • Purity :

    99.84
  • Solubility :

    DMSO : ≥ 100 mg/mL
  • Smiles :

    ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCO)C=C2)\C3=CC=CC=C3
  • Molecular Formula :

    C24H23ClO2
  • Molecular Weight :

    378.89
  • Precautions :

    H410
  • References & Citations :

    [1]Qiang Qv.et al.Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology.Feb;141 (2) :809-20. 25. (2000) .|[2]Tracy L. Taras et al.In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 77 (4-5) :271-9, (2001) .|[3]Unkila M, et, al. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013 Nov;138:107-15.|[4]Bruyniks N, et, al. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric. 2017 Jun; 20 (3) : 195-204.|[5]Pietrzak B A, et al. Posttreatment with ospemifene attenuates hypoxia-and ischemia-induced apoptosis in primary neuronal cells via selective modulation of estrogen receptors. Neurotoxicity Research, 2023, 41 (4) : 362-379.|[6]Burich RA, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012 Jan;19 (1) :96-103.
  • Shipping Conditions :

    Room Temperature
  • Storage Conditions :

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Scientific Category :

    Reference compound1
  • Clinical Information :

    Launched
  • Isoform :

    Caspase 3
  • CAS Number :

    [128607-22-7]

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide